Dr. Chagpar on Surgical Treatment of Patients With HER2+ Breast Cancer

Anees B. Chagpar, MD
Published: Wednesday, Jun 29, 2016


Anees B. Chagpar, MD, associate professor of Surgery (Oncology), director of The Breast Center at Smilow Cancer Hospital at Yale-New Haven, Yale Cancer Center, discusses how surgical oncologists should approach the treatment of patients with HER2-positive breast cancer.

In clinical practice, Chagpar explains that she surgically treats patients the same, regardless of HER2 status. If eligible, HER2-positive patients can choose breast conservation surgery versus mastectomy with reconstruction.

However, molecular subtypes such as HER2 play a role in surgery when surgical oncologists collaborate with medical oncologists, Chagpar says. This is because patients may be eligible to enroll in neoadjuvant clinical trials that can impact their surgical treatments.

Anees B. Chagpar, MD, associate professor of Surgery (Oncology), director of The Breast Center at Smilow Cancer Hospital at Yale-New Haven, Yale Cancer Center, discusses how surgical oncologists should approach the treatment of patients with HER2-positive breast cancer.

In clinical practice, Chagpar explains that she surgically treats patients the same, regardless of HER2 status. If eligible, HER2-positive patients can choose breast conservation surgery versus mastectomy with reconstruction.

However, molecular subtypes such as HER2 play a role in surgery when surgical oncologists collaborate with medical oncologists, Chagpar says. This is because patients may be eligible to enroll in neoadjuvant clinical trials that can impact their surgical treatments.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 16th Annual International Congress on the Future of Breast Cancer®Sep 29, 20182.0
School of Breast Oncology®: Mid-Year Video Update OnlineSep 30, 20182.0
Publication Bottom Border
Border Publication
x